CN112790250A - Infant formula milk powder for promoting intestinal health and preparation method thereof - Google Patents

Infant formula milk powder for promoting intestinal health and preparation method thereof Download PDF

Info

Publication number
CN112790250A
CN112790250A CN202110180540.2A CN202110180540A CN112790250A CN 112790250 A CN112790250 A CN 112790250A CN 202110180540 A CN202110180540 A CN 202110180540A CN 112790250 A CN112790250 A CN 112790250A
Authority
CN
China
Prior art keywords
infant formula
intestinal health
powder
promoting
milk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202110180540.2A
Other languages
Chinese (zh)
Inventor
魏立华
封肖颖
袁庆彬
王世杰
贾晓江
刘建光
刘海荣
荀一萍
冯丽莉
薛玉玲
张栋
闫尊浩
刘尧尧
杨婉秋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shijiazhuang Junlebao Dairy Co Ltd
Original Assignee
Shijiazhuang Junlebao Dairy Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shijiazhuang Junlebao Dairy Co Ltd filed Critical Shijiazhuang Junlebao Dairy Co Ltd
Publication of CN112790250A publication Critical patent/CN112790250A/en
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C21/00—Whey; Whey preparations
    • A23C21/06—Mixtures of whey with milk products or milk components
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C21/00—Whey; Whey preparations
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C21/00—Whey; Whey preparations
    • A23C21/02—Whey; Whey preparations containing, or treated with, microorganisms or enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C21/00—Whey; Whey preparations
    • A23C21/08—Whey; Whey preparations containing other organic additives, e.g. vegetable or animal products
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C21/00—Whey; Whey preparations
    • A23C21/10—Whey; Whey preparations containing inorganic additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/515—Animalis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention belongs to the technical field of food, and discloses infant formula milk powder for promoting intestinal health and a preparation method thereof. The 2' -fucosyllactose, the lactose-N-tetrasaccharide, the lactose-N-neotetraose and the bifidobacterium animalis subsp lactis i797 are added, so that the synergistic effect can be realized, the intestinal beneficial bacteria proliferation is promoted, the feed is suitable for infants, the intestinal flora of the infants can be adjusted, the immunity of the infants is enhanced, and the disease infection rate of the infants is reduced.

Description

Infant formula milk powder for promoting intestinal health and preparation method thereof
Technical Field
The invention belongs to the technical field of food, and relates to infant formula milk powder, in particular to infant formula milk powder for promoting intestinal health and a preparation method thereof.
Background
Human Milk Oligosaccharides (HMOs) are an important component of Human Milk, and are the second largest carbohydrate ingredient and the third largest nutrient ingredient which are second only to lactose, and the content of the HMOs in Human Milk is between 5 and 15 g/L. HMOs can support colonization of infant intestinal flora, inhibit pathogen infection, promote immunity and brain development, and play an important role in infant growth and development. HMOs are of a wide variety, and over 200 have been found to be present, with oligosaccharides of a much lower variety and content in cow's milk than in breast milk. The oligosaccharides in breast milk can be classified into 3 major groups, fucosylated oligosaccharides, sialylated oligosaccharides and nonfucosylated neutral oligosaccharides.
As the breast-feeding rate of infants in China is low, investigation shows that the pure breast-feeding rate of infants within half a year of birth in China only reaches 20.8 percent and is lower than the average level of the world. The infant formula milk powder is particularly important as a breast milk substitute in the infant population lacking breast feeding. Existing infant formulas are often supplemented with indigestible carbohydrates (NDC) having similar effects as certain HMOs, such as galacto-oligosaccharides (GOS), fructo-oligosaccharides (FOS), GOS/FOS mixtures, polydextrose, etc. However, NDC cannot replace all the functions of HMOs. Because various systems of infants are not developed and mature, the infants are easy to be infected, and the phenomena of incomplete intestinal flora and low immunity are easy to occur when the infants eat the conventional infant formula milk powder.
Disclosure of Invention
The invention aims to provide infant formula milk powder for promoting intestinal health so as to realize the functions of regulating infant intestinal flora and enhancing infant immunity;
it is another object of the present invention to provide a method for preparing the above infant formula for promoting intestinal health.
In order to achieve the purpose, the invention adopts the technical scheme that:
an infant formula for promoting gut health comprising bifidobacterium animalis subsp lactis i 797;
the effective components of the infant formula milk powder for promoting intestinal health comprise the following raw materials in parts by weight:
60-70 parts of cow milk/goat milk;
② nutritional agent: 9-12 parts of lactose, 8-10 parts of desalted whey powder, 6-8 parts of vegetable oil, 4-5 parts of 1, 3-dioleate-2-palmitic acid triglyceride, 1-3 parts of concentrated whey protein powder, 1-1.5 parts of 2' -fucosyllactose, 0.5-0.8 part of lactose-N-tetrasaccharide, 0.2-0.5 part of phospholipid, 0.15-0.3 part of lactose-N-neotetrasaccharide, 0.1-0.3 part of compound mineral substance, 0.1-0.15 part of compound vitamin, 0.05-0.1 part of calcium carbonate, 0.05-0.10 part of potassium hydroxide and 0.05-0.10 part of choline chloride;
③ nutrient enriching agent: 0.2-0.4 part of arachidonic acid powder, 0.1-0.2 part of fish oil powder and 0.01-0.05 part of nucleotide.
As a limitation, the raw materials for preparing the effective components of the infant formula milk powder for promoting intestinal health also comprise 0.01-0.05 parts of bifidobacterium animalis subsp lactis i797 bacterial powder;
bifidobacterium animalis subsp.lactis i797(Bifidobacterium animalis subsp. lactis i797) has been deposited at 20.8.8.2019 at the China general microbiological culture Collection center (national institute of patent and microorganism Collection) of China Committee for culture Collection, national institute of culture Collection, No. 3, West Lu No.1, North Cheng, and south Kogyo, Beijing, with the deposit numbers: CGMCC No.18403, which was first disclosed in a prior patent application No. 202010259210.8.
As another limitation, the content of Bifidobacterium animalis subsp lactis i797 in the infant formula for promoting intestinal health is 1 × 109～1×1010CFU/g。
As a third limitation, the vegetable oil is prepared by mixing 3-5 parts by weight of soybean oil, 2-4 parts by weight of rapeseed oil, 1-2 parts by weight of sunflower seed oil and 1-2 parts by weight of walnut oil.
As a fourth limitation, the cow/goat milk is prepared by standardizing raw cow/goat milk and separating impurities.
The invention also provides a preparation method of the infant formula milk powder for promoting intestinal health, which comprises the steps of pasteurizing cow milk/goat milk, adding a nutrient, uniformly mixing, homogenizing, sterilizing, concentrating, spray drying, adding a nutrition enhancer and i797 strain powder of bifidobacterium animalis subsp.
As a limitation, the pasteurization temperature is 60-70 ℃ and the time is 15-18 s;
the sterilization temperature is 85-90 ℃ and the sterilization time is 22-30 s.
As a second limitation, adding a nutritional agent, uniformly mixing, and preheating to 60-65 ℃ before homogenizing; the homogenizing pressure is 16-18 MPa.
As a third limitation, after concentration, the density is 1090-1140 kg/m3The concentrated milk of (1).
And as a fourth limitation, the air inlet temperature of the spray drying is 165-180 ℃, and the air outlet temperature is 80-90 ℃.
Due to the adoption of the technical scheme, compared with the prior art, the invention has the technical progress that:
the infant formula milk powder for promoting intestinal health is added with three breast milk oligosaccharides (HMOs) of 2' -fucosyllactose, lactose-N-tetraose and lactose-N-neotetraose, the three oligosaccharides enter a baby body and cannot be damaged by gastric acid, and reach small intestine and colon in an integral form, so that the effect of prebiotics is exerted, the proliferation of bifidobacteria is promoted, lactic acid and acetic acid are generated to reduce the pH value of intestinal tracts, and pathogenic bacteria are inhibited; the three oligosaccharides can also prevent the combination of pathogenic bacteria and surface receptors of epithelial cells of organisms, enhance the immunity and reduce the infection rate of diseases of infants;
the soybean oil, the rapeseed oil, the sunflower seed oil and the walnut oil are added into the infant formula milk powder for promoting intestinal health, the linoleic acid content in cow milk/goat milk is far lower than that of the cow milk, the linoleic acid content of the soybean oil and the sunflower seed oil is higher, the linoleic acid content in cow milk/goat milk can be supplemented, the rapeseed oil contains rich unsaturated fatty acid oleic acid and linoleic acid, and a certain amount of alpha-linolenic acid, and the proportion of the necessary fatty acid linoleic acid and the alpha-linolenic acid is adjusted through the compounding of several kinds of vegetable oil; in addition, 1, 3-dioleic acid-2-palmitic acid triglyceride is added into the infant formula milk powder, so that the content of sn-2-position palmitic acid is increased, DHA and ARA are added, the proportion of long-chain polyunsaturated fatty acid is increased, the composition of the infant formula milk powder is closer to that of fatty acid in breast milk, nutrition required by growth and development of infants is ensured, and the vision and brain development of infants are promoted;
the bifidobacterium animalis subsp lactis i797 is added into the infant formula milk powder for promoting intestinal health, the bifidobacterium animalis subsp lactis i797 is screened and separated from feces of a breast-fed healthy infant, and has the effects of improving diarrhea and regulating dyspepsia, after three kinds of HMOs (2' -fucosyllactose, lactose-N-tetrasaccharide and lactose-N-neotetrasaccharide) enter small intestines, the proliferation of the bifidobacterium animalis subsp lactis i797 can be promoted, the proliferation of bifidobacterium can enhance the intestinal immunity, and the incidence rate of baby diarrhea is reduced;
in conclusion, the infant formula milk powder for promoting intestinal health disclosed by the invention is closer to breast milk, so that the nutrition required by growth and development of infants is ensured, the healthy development of intestinal tracts can be promoted, and the immunity of infants is enhanced.
The infant formula milk powder for promoting intestinal health is suitable for infants.
Drawings
FIG. 1 is a comparison graph of OD values of Bifidobacterium animalis lactococcus species i797 after culture in control group and experimental groups 11 to 16 in example 8 of the present invention;
FIG. 2 is a graph showing a comparison of the concentration of sIgA in feces of control group and experimental groups 21 to 26 in example 8 of the present invention;
FIG. 3 is a comparison graph of pH values of feces of control group and experimental groups 21 to 26 in example 8 of the present invention;
FIG. 4 is a graph showing the comparison of the content of the bacterial population in feces of the control group and the experimental groups 21 to 26 in example 8 of the present invention.
Detailed Description
The present invention is further illustrated by the following specific examples, which are to be construed as merely illustrative, and not limitative of the remainder of the disclosure.
Example 1A method of preparing an infant formula for promoting intestinal health
The process of this example for preparing an infant formula for promoting gut health, comprising the following steps performed in sequence
1) Checking and accepting, and cleaning milk
Standardizing raw milk, and then separating impurities to obtain milk;
2) pregabacide
Pasteurizing 60kg of cow milk at 65 ℃ for 18s, and cooling to room temperature to obtain pasteurized milk;
3) mixing material
3.55kg of soybean oil, 2.67kg of rapeseed oil, 0.89kg of sunflower oil and 0.89kg of walnut oil are taken as the total vegetable oil. Wherein, the proportion relation LB1 of soybean oil, rapeseed oil, sunflower seed oil and walnut oil is 4: 3: 1: 1;
taking 105g of calcium carbonate, 66g of calcium chloride, 51.3g of potassium chloride, 36g of copper sulfate, 15g of sodium chloride, 12g of potassium iodide, 3g of magnesium sulfate, 9g of manganese sulfate, 1.5g of sodium selenite, 0.3g of ferrous sulfate and 0.9g of zinc sulfate as composite minerals;
121.25g of vitamin C, 12.12g of vitamin E, 6.06g of pantothenic acid, 6.06g of nicotinamide and 2.27g of vitamin B20.64g vitamin A, 0.76g vitamin B10.61g of vitamin B60.08g folic acid, 0.045g vitamin K10.015g vitamin D, 0.045g vitamin B12And 0.045g biotin as a multivitamin;
12kg of lactose, 10kg of desalted whey powder, 8kg of vegetable oil, 5kg of 1, 3-dioleoyl-2-palmitic acid triglyceride powder, 3kg of concentrated whey protein powder, 1.2kg of 2' -fucosyllactose, 0.6kg of lactose-N-tetraose, 0.5kg of phospholipid, 0.2kg of lactose-N-neotetraose, 0.3kg of compound mineral, 0.15kg of compound vitamin, 0.1kg of calcium carbonate, 0.1kg of potassium hydroxide and 0.08kg of choline chloride are added into pasteurized milk, and the mixture is stirred, mixed uniformly and dissolved sufficiently to obtain feed liquid M1.
4) Preheating feed liquid M1 to 60 deg.C, homogenizing under 18MPa, heating to 85 deg.C for sterilizing for 30s, and concentrating by four-effect falling film evaporation to obtain solution with density of 1090kg/M3The concentrated milk of (1).
5) Pumping the concentrated milk into a dry state by a high-pressure pumpSpray drying in a drying tower at air inlet temperature of 180 deg.C and air exhaust temperature of 80 deg.C, adding 0.4kg arachidonic acid powder, 0.2kg fish oil powder, 0.05kg nucleotide and 0.05kg Bifidobacterium animalis subsp lactis i797 powder into the powder, stirring, and mixing completely to obtain infant formula milk powder (labeled as N1) for promoting intestinal health, wherein the content of Bifidobacterium animalis subsp lactis i797 is 1.0 × 1010CFU/g. The infant formula N1 for promoting intestinal health prepared by the embodiment is suitable for infants.
Example 2-6 preparation method of infant formula milk powder for promoting intestinal health
Examples 2 to 6 are methods of preparing infant formulas for promoting intestinal health, respectively, which have substantially the same procedure as in example 1, except for the differences in the amounts of raw materials and the control parameters associated with the operation process, as shown in tables 1 to 3:
table 1 raw material amount schedule of composite minerals
Figure BDA0002941375500000061
TABLE 2 raw material usage of multivitamins
Figure BDA0002941375500000062
Figure BDA0002941375500000071
Table 3 summary of raw material amounts and parameters in infant formula for promoting intestinal health
Figure BDA0002941375500000072
Figure BDA0002941375500000081
The contents of the other portions of examples 2 to 6 are the same as those of example 1.
Example 7 determination of fatty acid content of infant formula to promote gut health
The contents of linoleic acid (C18:2) and alpha-linolenic acid (C18:3) in the infant formula milk powder N1-N6 (12.9g of milk powder is added into 90mL of warm boiled water at about 50 ℃), breast milk (collected by volunteers), traditional formula milk powder 1 (prepared according to the specification), traditional formula goat milk powder 1 (prepared according to the specification) for promoting intestinal health prepared in the examples 1-6 are respectively detected according to the method in determination of fatty acid in food (GB 5009.168-2016), and the specific results are as follows:
table 2 summary of fatty acid content measurement results
Figure BDA0002941375500000091
Polyunsaturated fatty acids are essential for maintaining normal growth and development of the infant, particularly for promoting the growth and development of the central nervous system of the infant. Linoleic acid is a precursor form of arachidonic acid, can be converted into a plurality of bioactive molecules, is an acid metabolized into prostaglandin and other eicosanoid substance molecules, can promote the brain and eyesight development of infants, can also promote the metabolism of the infants and can improve the immunity. The alpha-linolenic acid exists in DHA and retina of human cranial nerves in large quantity, is extremely important for the development of infant brains, can promote the synthesis of nucleic acid proteins and monoamine neurotransmitters in the brains, and has important effects on the formation, growth, proliferation, differentiation and maturation of cerebral neurons, glial cells and nerve conduction synapses. The alpha-linolenic acid can enhance the permeability of cerebral nerve membranes and presynaptic and postsynaptic membranes, smooth nerve information transmission path, improve nerve reflex capacity, and further enhance the thinking ability, memory ability and stress ability of people.
As can be seen from Table 2, the infant formula milk powder for promoting intestinal health provided by the invention contains fatty acids with a proportion closer to that of breast milk, is more suitable for infants, and is superior to the traditional formula milk powder in paragraph 1 and the traditional formula goat milk powder in paragraph 1. Among them, the infant formula N1 for promoting intestinal health prepared in example 1 is closest to breast milk.
Example 8 Effect of infant formula for promoting intestinal health on intestinal health
One) in vitro proliferation effect of HMOs on Bifidobacterium animalis subsp lactis i797 with different proportions
The 2' -fucosyllactose, the lacto-N-tetraose and the lacto-N-neotetraose in the examples 1 to 6 were mixed in proportion, and the obtained HMOs1 to HMOs6 were added to the MRS medium in a one-to-one correspondence manner at a mass concentration of 0.2%, thereby obtaining experimental MRS media 1 to 6.
The experiment is divided into a control group and experiment groups 11-16, wherein the control group is prepared by 1% (10%) of activated bifidobacterium animalis subsp lactis i7976CFU/mL) in MRS culture medium without any other substances, and experimental groups 11-16 are obtained by inoculating 1% (10%) of activated Bifidobacterium animalis subsp lactis i797 in an experimental group6CFU/mL) is inoculated in experimental MRS culture media 1-6 correspondingly, and after anaerobic culture is carried out for 24 hours at 37 ℃ on a control group and experimental groups 11-16, the OD value of each group of culture solution is measured at the wavelength of 600 nm.
As shown in FIG. 1, the OD values of the cultured Bifidobacterium animalis L797 in the experimental groups 11-16 were significantly higher than those of the control group. The above experiments prove that 2 '-fucosyllactose, lacto-N-tetraose and lacto-N-neotetraose can promote the growth of bifidobacterium animalis subsp lactis i797, wherein the ratio of the 2' -fucosyllactose, lacto-N-tetraose and lacto-N-neotetraose in example 1 has better effect on the growth of bifidobacterium animalis subsp lactis i 797.
Second) Effect of infant formula promoting intestinal health on mouse intestinal tract
The control formula was prepared according to the method and amount of example 1, except that 2' -fucosyllactose, lacto-N-tetraose, lacto-N-neotetraose and bifidobacterium animalis subsp lactis i797 powder were not added to the control formula D1.
Selecting 42C 57BL/6 mice, randomly dividing the mice into 7 groups, wherein each group comprises 6 mice, namely a control group and 21-26 experimental groups, wherein the control group is intragastrically infused with 0.2mL of control formula milk powder (prepared by the infusion method in example 7) in the morning every day, the experimental groups 21-26 are intragastrically infused with 0.2mL of infant formula milk powder N1-N6 (prepared by the infusion method in example 7) for promoting intestinal health, the infant formula milk powder is infused with 0.2mL of infant formula milk powder for promoting intestinal health, the infusion is continued for 2 weeks, and feces are taken before the beginning and after the end of the intragastrically infused experiment for sIgA, pH and fecal flora detection and analysis. Wherein, the fecal flora detection analysis comprises the following steps: a) coating the feces on LBS culture medium, performing aerobic culture at 37 ℃ for 48h, and calculating the viable count of lactobacillus; b) coating the feces on a BBL agar culture medium, performing anaerobic culture at 37 ℃ for 48h, and calculating the viable count of the bifidobacteria; c) coating the feces on GAM culture medium, performing anaerobic culture at 37 deg.C for 48 hr, and calculating viable count of Bacteroides; d) and (3) coating the excrement on eosin methylene blue agar, carrying out aerobic culture at 37 ℃ for 48 hours, and calculating the viable count of the enterobacteria.
sIgA is an important immune substance and especially has important significance for maintaining the immune function of immature intestinal tracts of infants. The higher the sIgA concentration in the excrement is, the more positive the effects of enhancing immunity, preventing infection and promoting growth and development are.
As can be seen from FIG. 2, after the experiment is finished, the sIgA concentration in the feces of the mice in the control group and the experiment group of 21-26 is gradually increased compared with that before the experiment is started, which indicates that the intestinal tracts of the mice in the two groups are normally developed. However, at 14 days, the sIgA concentration in the feces of mice in experimental groups 21-26 was significantly higher than that in the control group, with the experimental group 1 being the most preferred. The experiments show that the 2' -fucosyllactose, the lactose-N-tetrasaccharide, the lactose-N-neotetrasaccharide and the bifidobacterium animalis subsp.
The pH value of the excrement is close to that of the colon, the pH value of the colon can be estimated by measuring the pH value of the excrement, and the reduction of the pH value of the colon is beneficial to inhibiting the growth and proliferation of saprophytic bacteria, so that intestinal diseases such as enteritis, colon cancer and the like are prevented/treated, and the intestinal health is promoted. Thus, a lower pH value of the stool indicates a healthier intestine.
As can be seen from FIG. 3, at the end of the experiment, the pH of the feces of the mice in the experimental groups 21-26 was significantly reduced compared to the control group, wherein the pH was optimal in the experimental group 1. The experiments show that the pH of intestinal tracts of suckling mice can be reduced by adding 2' -fucosyllactose, lactose-N-tetrasaccharide, lactose-N-neotetrasaccharide and bifidobacterium animalis subsp lactis i797 bacterial powder.
The flora content in the excrement can reflect the flora content in the intestinal tract, and the lactobacillus and the bifidobacterium are beneficial bacteria in the intestinal tract, and the more the lactobacillus and the bifidobacterium are, the healthier the intestinal tract is; bacteroides and Enterobacter are harmful intestinal bacteria, and the lower the number, the healthier the intestinal tract.
As can be seen from fig. 4, at the end of the experiment, compared with the control group, the numbers of useful intestinal bacteria lactobacillus and bifidobacterium of the suckling mice in the experimental groups 21-26 are obviously increased, and the numbers of two harmful bacteria bacteroides and enterobacter are obviously reduced, wherein the experimental group 1 is the best. The experiments show that the addition of 2' -fucosyllactose, lactose-N-tetraose, lactose-N-neotetraose and bifidobacterium animalis subsp lactis i797 bacterial powder can promote the proliferation of beneficial bacteria in intestinal tracts, and the composite use effect of the two is more obvious.
In conclusion, the infant formula milk powder for promoting intestinal health is added with the 2' -fucosyllactose, the lactose-N-tetraose, the lactose-N-neotetraose and the bifidobacterium animalis subsp lactis i797 bacterial powder in a reasonable proportion, so that the intestinal immunity can be enhanced, the proliferation of beneficial bacteria in the intestinal tract can be promoted, and the healthy development of the intestinal tract of an infant can be further promoted.

Claims (10)

1. An infant formula for promoting intestinal health, characterized in that,
the infant formula milk powder for promoting intestinal health contains bifidobacterium animalis subsp lactis i 797;
the effective components of the infant formula milk powder for promoting intestinal health comprise the following raw materials in parts by weight:
60-70 parts of cow milk/goat milk;
② nutritional agent: 9-12 parts of lactose, 8-10 parts of desalted whey powder, 6-8 parts of vegetable oil, 4-5 parts of 1, 3-dioleate-2-palmitic acid triglyceride, 1-3 parts of concentrated whey protein powder, 1-1.5 parts of 2' -fucosyllactose, 0.5-0.8 part of lactose-N-tetrasaccharide, 0.2-0.5 part of phospholipid, 0.15-0.3 part of lactose-N-neotetrasaccharide, 0.1-0.3 part of compound mineral substance, 0.1-0.15 part of compound vitamin, 0.05-0.1 part of calcium carbonate, 0.05-0.10 part of potassium hydroxide and 0.05-0.10 part of choline chloride;
③ nutrient enriching agent: 0.2-0.4 part of arachidonic acid powder, 0.1-0.2 part of fish oil powder and 0.01-0.05 part of nucleotide.
2. The infant formula for promoting intestinal health according to claim 1, wherein the raw materials for preparing the effective components of the infant formula for promoting intestinal health further comprise 0.01-0.05 parts of bifidobacterium animalis subsp.
3. The enteral health-promoting infant formula according to claim 1 or 2, wherein the content of Bifidobacterium animalis subsp9~1×1010CFU/g。
4. The infant formula for promoting intestinal health according to claim 1 or 2, wherein the vegetable oil is a mixture of soybean oil, rapeseed oil, sunflower oil and walnut oil.
5. The enteral infant formula according to claim 1 or 2, wherein the cow/goat milk is raw cow/goat milk, which is standardized and separated from impurities.
6. The preparation method of the infant formula milk powder for promoting the intestinal health, according to any one of claims 1 to 5, is characterized in that cow milk/goat milk is pasteurized, added with a nutrient and mixed uniformly, homogenized, sterilized, concentrated, spray-dried, then added with a nutrition enhancer and animal bifidobacterium lactis subsp.i 797 bacterial powder and mixed uniformly to obtain the infant formula milk powder for promoting the intestinal health.
7. The method for preparing infant formula for promoting intestinal health according to claim 6, wherein the pasteurization temperature is 60-70 ℃ for 15-18 s;
the sterilization temperature is 85-90 ℃ and the sterilization time is 22-30 s.
8. The method for preparing infant formula milk powder for promoting intestinal health according to claim 6 or 7, wherein the infant formula milk powder is further preheated to 60-65 ℃ after the nutritional agent is added and mixed uniformly and before homogenization; the homogenizing pressure is 16-18 MPa.
9. The method for preparing an infant formula for promoting intestinal health according to claim 6 or 7, wherein the concentration results in a density of 1090 to 1140kg/m3The concentrated milk of (1).
10. The method for preparing infant formula milk powder for promoting intestinal health according to claim 6 or 7, wherein the air inlet temperature of the spray drying is 165-180 ℃ and the air outlet temperature is 80-90 ℃.
CN202110180540.2A 2020-12-04 2021-02-08 Infant formula milk powder for promoting intestinal health and preparation method thereof Withdrawn CN112790250A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011411002 2020-12-04
CN2020114110021 2020-12-04

Publications (1)

Publication Number Publication Date
CN112790250A true CN112790250A (en) 2021-05-14

Family

ID=75815005

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110180540.2A Withdrawn CN112790250A (en) 2020-12-04 2021-02-08 Infant formula milk powder for promoting intestinal health and preparation method thereof

Country Status (1)

Country Link
CN (1) CN112790250A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113907144A (en) * 2021-10-22 2022-01-11 内蒙古伊利实业集团股份有限公司 Infant formula food added with HMO and application thereof
CN114208893A (en) * 2021-11-30 2022-03-22 内蒙古伊利实业集团股份有限公司 Formula milk powder capable of improving intestinal microenvironment health and preparation method and application thereof
CN114223723A (en) * 2021-12-13 2022-03-25 黑龙江飞鹤乳业有限公司 Nutritional composition, food product comprising the same and use of the nutritional composition
CN114271340A (en) * 2021-11-30 2022-04-05 内蒙古伊利实业集团股份有限公司 Formula milk powder containing lactose-N-tetrasaccharide and preparation method and application thereof
CN115918733A (en) * 2022-11-30 2023-04-07 内蒙古伊利实业集团股份有限公司 Formula milk powder and preparation method thereof
CN116746683A (en) * 2023-08-01 2023-09-15 河北源民生物科技有限公司 Anti-dyspepsia flatulence and absorption promoting bifidobacterium animalis subspecies lactis BAL-28, fermentation product, flora CW and application

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113907144A (en) * 2021-10-22 2022-01-11 内蒙古伊利实业集团股份有限公司 Infant formula food added with HMO and application thereof
CN114208893A (en) * 2021-11-30 2022-03-22 内蒙古伊利实业集团股份有限公司 Formula milk powder capable of improving intestinal microenvironment health and preparation method and application thereof
CN114271340A (en) * 2021-11-30 2022-04-05 内蒙古伊利实业集团股份有限公司 Formula milk powder containing lactose-N-tetrasaccharide and preparation method and application thereof
CN114208893B (en) * 2021-11-30 2023-11-10 内蒙古伊利实业集团股份有限公司 Formula milk powder capable of improving intestinal microenvironment health and preparation method and application thereof
CN114223723A (en) * 2021-12-13 2022-03-25 黑龙江飞鹤乳业有限公司 Nutritional composition, food product comprising the same and use of the nutritional composition
CN115918733A (en) * 2022-11-30 2023-04-07 内蒙古伊利实业集团股份有限公司 Formula milk powder and preparation method thereof
CN116746683A (en) * 2023-08-01 2023-09-15 河北源民生物科技有限公司 Anti-dyspepsia flatulence and absorption promoting bifidobacterium animalis subspecies lactis BAL-28, fermentation product, flora CW and application

Similar Documents

Publication Publication Date Title
CN112790250A (en) Infant formula milk powder for promoting intestinal health and preparation method thereof
CN112868800A (en) Infant formula milk powder containing breast milk oligosaccharide for improving immunity and preparation method thereof
CN108741083A (en) Promote the neutral human milk oligosaccharides of beneficial bacteria growth
CN1838888A (en) Infant or follow-on formula
AU2020294253B2 (en) Nutritional Composition For Promoting Intestinal Health
CN103763940A (en) Synbiotic combination of probiotic and human milk oligosaccharides to promote growth of beneficial microbiota
MX2010012905A (en) Probiotics to improve gut microbiota.
CN112535218A (en) Maternal emulsified infant formula milk powder for promoting intelligence development and intestinal health and preparation method and application thereof
CN109287920A (en) A kind of solid beverage and preparation method thereof of multicomponent complex and multi-joint probiotics
CN103271274B (en) Nutrient health-care porridge
CN111480849B (en) Composite probiotic microcapsule powder for mother emulsification and preparation method and application thereof
US20240306690A1 (en) Mixture of hmos and bifidobacteria
CN110679813A (en) Probiotic health-care beverage for losing weight
TWI626893B (en) Method for inhibiting pathogens using a nutritional composition
WO2018067002A1 (en) Normalization of the intestinal microbiota composition in infants or toddlers fed with an amino acid-based nutritional composition
CN112075504A (en) Infant formula milk powder for enhancing immunity
CN112167348A (en) Formula milk powder for promoting growth and development of children and preparation method thereof
CN110692884A (en) Probiotic health-care beverage assisting in reducing hypertension, hyperglycemia and hyperlipidemia
CN112535217A (en) Maternal emulsified hypoallergenic fresh and alive infant formula milk and preparation method thereof
CN116286458B (en) Lactobacillus plantarum LZ010 capable of reducing blood pressure and blood fat and application thereof
CN107467193A (en) Full nutrition special medicine purposes formula food of a kind of pulvis based on goat milk and preparation method thereof
CN114223728B (en) Premature/low birth weight infant formula containing prebiotics and probiotics
CN109601981A (en) It is a kind of suitable for premature labor and nutrition spy's dietary seafood of low birth weight infant and preparation method thereof
CN111820284A (en) Infant formula milk powder for optimizing amino acid pattern and improving immunity and preparation method thereof
CN112806577A (en) Prebiotic probiotic synergistic combinations for butyric acid production

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20210514

WW01 Invention patent application withdrawn after publication